Gowling WLG advised Britannia Bud Canada Holdings Inc., trading as Britannia Life Sciences in respect of its strategic partnership with a UK laboratory services provider.
BLS is a Canadian incorporated wellness company with a focus on the UK and European cannabis markets. It has emerged as an expert in novel food applications and analytical testing relating to CBD and other cannabis-related products.
Laboratory services also include product formulation and development, cosmetic product safety reports, microbiological testing, global compliance and clinical trials for the cosmetic and household goods industry. The partnership is a cornerstone of BLS’s strategy to become the leading UK provider of laboratory services and product development support for the cosmetics, food and nutraceutical industries and a key step towards its previously announced proposed listing on the Canadian Securities Exchange in Q2 of 2021, by way of a reverse takeover with Rise Life Science Corp. (CSE: RLSC).
Gowling WLG’s legal advisory team comprised Charles Bond (Picture), Samantha Myers, Alex Davidson, Alistair Connor (Corporate), Zoe Fatchen (Tax), Mathilda Davidson (IP), Kiran Gosal (Employment) in the UK and Lorraine Mastersmith (Securities law) from the firm’s Ottawa office.
Involved fees earner: Charles Bond – Gowling WLG; Mathilda Davidson – Gowling WLG; Alex Davidson – Gowling WLG; Zoe Fatchen – Gowling WLG; Kiran Gosal – Gowling WLG; Lorraine Mastersmith – Gowling WLG; Samantha Myers – Gowling WLG;
Law Firms: Gowling WLG;
Clients: Britannia Bud Canada Holdings Inc.;